<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer

dc.contributor.authorSharbeen, George
dc.contributor.authorKokkinos, John
dc.contributor.authorSchulstad, Grace
dc.contributor.authorPandzic, Elvis
dc.contributor.authorYoukhana, Janet
dc.contributor.authorMa, Zerong
dc.contributor.authorIgnacio, Rosa Mistica C.
dc.contributor.authorRaina, Aparna S.
dc.contributor.authorChiang, Shannon
dc.contributor.authorBoyer, Cyrille
dc.contributor.authorHaghighi, Koroush S.
dc.contributor.authorGunawarman, Matthew
dc.contributor.authorGoldstein, David
dc.contributor.authorGebski, Val
dc.contributor.authorPajic, Marina
dc.contributor.authorDavis, Meagan E.
dc.contributor.authorArkell, Oliver S. M.
dc.contributor.authorKopecky, Chantal
dc.contributor.authorGonzales-Aloy, Estrella
dc.contributor.authorIshak, Alexander
dc.contributor.authorErkan, Mert
dc.contributor.authorMorton, Jennifer P.
dc.contributor.authorKavallaris, Maria
dc.contributor.authorGunning, Peter W.
dc.contributor.authorHardeman, Edna C.
dc.contributor.authorJohns, Amber
dc.contributor.authorGill, Anthony J.
dc.contributor.authorWhan, Renee M.
dc.contributor.authorMawson, Amanda
dc.contributor.authorPitiyarachchi, Omali
dc.contributor.authorMcCarroll, Joshua A.
dc.contributor.authorPhillips, Phoebe A.
dc.date.accessioned2026-11-05T11:07:18Z
dc.date.issued2026
dc.description.abstractThe microtubule protein beta III-tubulin is a prognostic, pro-survival, and chemoresistance factor in multiple malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the precise survival mechanisms controlled by beta III-tubulin in cancer remain unknown. Here, we discovered a link between beta III-tubulin and the activation of caspase 8-mediated extrinsic apoptosis. Silencing beta III-tubulin in PDAC cells activated caspase 8, leading to decreased cell viability and growth both in vitro and in vivo. beta III-tubulin knockdown also increased the sensitivity of PDAC cells to extrinsic cell death signals, including TNF-related apoptosis-inducing ligand (TRAIL), TNF alpha, and FasL. Furthermore, we demonstrated that beta III-tubulin knockdown in PDAC cells, in the absence or presence of TRAIL, increased diffusion and clustering of the TRAIL death receptor DR5 at the cell membrane, inducing extrinsic apoptosis. Nanoparticle delivery of beta III-tubulin siRNA to mouse PDAC tumours reduced tumour growth and increased responsiveness to TRAIL therapy. In patient-derived human PDAC explants, beta III-tubulin silencing reduced tumour cell frequency and improved sensitivity to TRAIL. Finally, we showed that high beta III-tubulin expression in the human PDAC stroma was independently prognostic for poor overall survival. Taken together, silencing beta III-tubulin represents an innovative strategy to activate a suicide signal in PDAC cells and render them more sensitive to microenvironment- and chemotherapy-derived death signals.
dc.description.issue1
dc.description.pages547
dc.description.sponsorshipNational Health and Medical Research Council Ideas Grant (Phillips, Sharbeen, APP2002707); NHMRC project grant (Phillips, McCarroll, Goldstein, APP1144108); Tour de Cure Senior Research Grant (Phillips, McCarroll, Goldstein, RSP-235-2020); Tour de Cure Pioneering Research Grant (Sharbeen, Phillips, Goldstein, RSP-255-2020); Cancer Institute NSW Translational Program Grant (Phillips, Goldstein, 2020/TPG2100); Tour de Cure PhD Support Scholarship (Kokkinos, Phillips, Goldstein, RSP-011-18/19); Cancer Research UK Institute Award (Morton, A29996); Australian Government Research Training Program Scholarship and UNSW Sydney Scientia PhD Scholarship (Kokkinos); Cancer-Institute NSW Career Development Fellowship (Sharbeen, CDF181166); Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group Senior Research Fellowship (Funded by Cancer Institute NSW Translational Cancer Research Capacity Building Grant, 2021/CBG0003, Sharbeen); NSW Health Advanced Therapeutics Impact Grant (Sharbeen, Phillips, McCarroll, Haghighi, Goldstein); Avner Pancreatic Cancer Foundation Innovation Grant (Phillips, McCarroll, Goldstein, and Sharbeen, APCF0050618); Cancer-Institute NSW ECF (Sharbeen, 13/ECF/1-to08); Cancer Institute NSW Translational Program Grant (2020/TPG2100; Goldstein, Phillips, Pajic), NSW Health Advanced Therapeutics Impact Grant (Sharbeen, Phillips, Goldstein, McCarroll); Olivia Lambert Foundation (McCarroll), and Cancer Australia (Phillips, McCarroll and Goldstein, APP1126736); Philanthropic support from Mr Paul Dainty, Dr Marjorie O'Neil, Dr Keri Spooner, and the Ippolito family: Ignazia, Ilana and Stefan.
dc.description.volume17
dc.identifier.doi10.1038/s41419-026-08657-6
dc.identifier.issn2041-4889
dc.identifier.urihttps://doi.org/10.1038/s41419-026-08657-6
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11438
dc.identifier.wosWOS:001786045400001
dc.language.isoen
dc.publisherSPRINGERNATURE
dc.relation.fundingCancer Research UK Institute Award (A29996)
dc.relation.fundingTour de Cure Senior Research Grant (RSP-235-2020) Tour de Cure Pioneering Research Grant (RSP-255-2020) Cancer Institute NSW Translational Program Grant (2020/TPG2100) Avner Pancreatic Cancer Foundation Innovation Grant (APCF0050618) Cancer Institute NSW T
dc.relation.funding- Tour de Cure Pioneering Research Grant (RSP-255-2020) - NSW health Advanced Therapeutics Impact Grant - Maridulu Budyari Gumal Sydney Partnership for Health, Education, Research and Enterprise [SPHERE] Cancer Clinical Academic Group Senior Research Fello
dc.relation.funding- Australian Government Research Training Program Scholarship and UNSW Sydney Scientia PhD Scholarship - Tour de Cure PhD Support Scholarship (RSP-011-18/19)
dc.relation.fundingDepartment of Health | National Health and Medical Research Council (NHMRC)(National Health & Medical Research Council (NHMRC) of Australia)
dc.relation.fundingDepartment of Health | National Health and Medical Research Council (NHMRC) [APP2002707, APP1144108]
dc.relation.hasversion10.1038/s41419-026-08657-6
dc.relation.ispartofCELL DEATH & DISEASE
dc.subjectGENE-EXPRESSION
dc.subjectNAB-PACLITAXEL
dc.subjectSTELLATE CELLS
dc.subjectRESISTANCE
dc.subjectIDENTIFICATION
dc.subjectTUBB3
dc.subjectCHEMORESISTANCE
dc.subjectPROLIFERATION
dc.subjectTUMORIGENESIS
dc.subjectGEMCITABINE
dc.subjectCell Biology
dc.titleβIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.issue1
oaire.citation.volume17
person.identifier.orcid0000-0001-9854-6375
person.identifier.orcid0000-0002-6373-1930
person.identifier.orcid0000-0002-5228-0919
person.identifier.ridHNJ-2164-2023
person.identifier.ridA-5436-2009
person.identifier.ridAAJ-5113-2021
person.identifier.ridF-8872-2012
person.identifier.ridE-9058-2010
person.identifier.ridD-4215-2015
person.identifier.ridE-8481-2010
person.identifier.ridJ-5240-2014

Files

Collections